Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1491-1499

  Chavez Blanco A ^a,b   De La Cruz Hernandez E ^a   Dominguez G I ^a   Rodriguez Cortez O ^b   Alatorre, B ^a   Perez Cardenas E ^a   Chacon Salinas R ^b   Trejo Becerril, C ^a   Taja Chayeb, L ^a   Trujillo, J E ^a   Contreras Paredes, A ^a   Dueñas González, Alfonso ^c  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

Hydralazine; NK cells; NKG2D ligands; Valproate

Indexed keywords

HYDRALAZINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; VALPROIC ACID;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYDRALAZINE; KILLER CELLS, NATURAL; LIGANDS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEIN BINDING; UP-REGULATION; VALPROIC ACID;

EID: 80054797849     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1144     Document Type: Article

References (49)

1. Zhu WG and Otterson GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anti-Cancer Agents 3: 187-189, 2003.
2. Hellebrekers DM, Griffioen AW and van Engeland M: Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta 1775: 76-91, 2007. (Pubitemid 44895568)
3. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragno M and Boccurzzi G: Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191: 465-472, 2006. (Pubitemid 44830622)
4. Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S and Grant S: The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64: 2590-2600, 2004. (Pubitemid 38523917)
5. Yeow WS, Ziauddin MF, Maxhimer JB, Shamimi-Noori S, Baras A, Chua A, Schrump DS and Nguyen DM: Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. Br J Cancer 94: 1436-1445, 2006. (Pubitemid 43772278)
6. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, Cabrera G and Duenas-Gonzalez A: Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 6: 2, 2006.
7. Tomasi TB, Magner WJ and Khan AN: Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother 55: 1159-1184, 2006. (Pubitemid 43992044)
8. Campoli M and Ferrone S: HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27: 5869-5885, 2008.
9. Karpf AR: A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 1: 116-120, 2006.
10. Fernández-Morera JL, Calvanese V, Rodríguez-Rodero S, Menéndez-Torre E and Fraga MF: Epigenetic regulation of the immune system in health and disease. Tissue Antigens 76: 431-439, 2010.
11. Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES and Lanier LL: NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med 197: 1245-1253, 2003. (Pubitemid 36617771)
12. Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U, Rammensee HG and Steinle A: Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol 33: 194-203, 2003. (Pubitemid 36157657)
13. Moretta L and Moretta A: Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23: 255-259, 2004. (Pubitemid 38294490)
14. Bryceson YT and Ljunggren HG: Tumor cell recognition by the NK cell activating receptor NKG2D. Eur J Immunol 38: 2927-2968, 2008.
15. Waldhauer I and Steinle A: NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943, 2008.
16. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM and Hayakawa Y: NKG2D function protects the host from tumor initiation. J Exp Med 202: 583-588, 2005. (Pubitemid 41248410)
17. Hayakawa Y and Smyth MJ: Innate immune recognition and suppression of tumors. Adv Cancer Res 95: 293-322, 2006. (Pubitemid 44066529)
18. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Old LJ and Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111, 2001. (Pubitemid 32391043)
19. Dunn GP, Old LJ and Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360, 2004. (Pubitemid 38680426)
20. Bitzer M, Armeanu S, Prinz F, Ungerechts G, Wybranietz W, Spiegel M, Bernlöhr C, Cecconi F, Gregor M, Neubert WJ, Schulze-Osthoff K and Lauer UM: Caspase-8 and Apaf-1-independent caspase-9 activation in Sendai virus-infected cells. J Biol Chem 277: 29817-19824, 2002.
21. Aktas E, Can U, Sema Bilgic K, Erten G and Deniz G: Relation-ship between CD107a expression and cytotoxic activity. Cell Immunol 254: 149-154, 2009.
22. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM and Hayakawa Y: NKG2D function protects the host from tumor initiation. J Exp Med 202: 583-588, 2005. (Pubitemid 41248410)
23. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM and Raulet DH: NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580, 2008.
24. Gonzalez S, Groh V and Spies T: Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 298: 121-138, 2006.
25. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M and Spies T: Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 93: 12445-12450, 1996. (Pubitemid 26367163)
26. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD and Tabi Z: Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 180: 7249-7258, 2008.
27. Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S and Konishi I: Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58: 641-652, 2009.
28. Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D and Ugurel S: Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 15: 5208-5215, 2009.
29. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A and Salih HR: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65: 6321-6329, 2005. (Pubitemid 40994418)
30. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, Hofsteenge J, Gratwohl A, Tichelli A, Paluszewska M, Wiktor-Jedrzejczak W, Kalberer CP and Wodnar-Filipowicz A: NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111: 1428-1436, 2008. (Pubitemid 351213430)
31. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M and Zocchi MR: Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 23: 641-648, 2009.
32. Zhang C, Wang Y, Zhou Z, Zhang J and Tian Z: Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58: 1275-1285, 2009.
33. Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, Syono Y, Ota S, Kondo T, Asaka M and Imamura M: Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 21: 2103-2108, 2007. (Pubitemid 47423800)
34. Tang KF, He CX, Zeng GL, Wu J, Song GB, Shi YS, Zhang WG, Huang AL, Steinle A and Ren H: Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine. Biochem Biophys Res Commun 370: 578-583, 2008.
35. Kim JY, Bae JH, Lee SH, Lee EY, Chung BS, Kim SH and Kang CD: Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide. J Immunother 31: 475-486, 2008.
36. Fu HY, Shen JZ, Wu Y, Shen SF, Zhou HR and Fan LP: Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells. Oncol Rep 24: 335-343, 2010.
37. Mora-García Mde L, Duenas-González A, Hernández- Montes J, De la Cruz-Hernández E, Pérez-Cárdenas E, Weiss-Steider B, Santiago-Osorio E, Ortíz-Navarrete VF, Rosales VH, Cantú D, Lizano-Soberón M, Rojo-Aguilar MP and Monroy-García A: Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med 4: 55, 2006.
38. Arce C, Pérez-Plasencia C, González-Fierro A, de la Cruz-Hernández E, Revilla-Vázquez A, Chávez-Blanco A, Trejo-Becerril C, Pérez-Cárdenas E, Taja-Chayeb L, Bargallo E, Villarreal P, Ramírez T, Vela T, Candelaria M, Camargo MF, Robles E and Dueñas-González A: A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 1: E98, 2006.
39. De la Cruz-Hernández E, Perez-Plasencia C, Pérez-Cardenas E, Gonzalez-Fierro A, Trejo-Becerril C, Chávez-Blanco A, Taja-Chayeb L, Vidal S, Gutiérrez O, Dominguez GI, Trujillo JE and Duenas- González A: Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. Oncol Rep 25: 399-407, 2011.
40. Zhang Y and Dufau ML: Repression of the luteinizing hormone receptor gene promoter by cross talk among EAR3/COUP-TFI, Sp1/Sp3, and TFIIB. Mol Cell Biol 23: 6958-6972, 2003. (Pubitemid 37214663)
41. Clem BF and Clark BJ: Association of the mSin3A-histone deacetylase 1/2 corepressor complex with the mouse steroidogenic acute regulatory protein gene. Mol Endocrinol 20: 100-113, 2006. (Pubitemid 43011673)
42. Estève PO, Chin HG and Pradhan S: Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 282: 2615-2625, 2007.
43. Candelaria M, Herrera A, Labardini J, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Pérez-Cárdenas E, de la Cruz-Hernández E, Arias-Bofill D, Vidal S, Cervera E and Dueñas-Gonzalez A: Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann Hematol 90: 379-387, 2001.
44. Candelaria M, Gallardo-Rincón D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, González-Fierro A, Chávez-Blanco A, de la Cruz-Hernández E, Camargo MF, Trejo-Becerril C, Pérez- Cárdenas E, Pérez-Plasencia C, Taja-Chayeb L, Wegman-Ostrosky T, Revilla-Vazquez A and Dueñas-González A: A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 18: 1529-1538, 2007.
45. Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, González-Fierro A, de la Cruz-Hernandez E, Perez-Cardenas E, Taja-Chayeb L, Arias-Bofill D, Candelaria M, Vidal S and Dueñas-González A: A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol Oct 8, 2010. [Epub ahead of print].
46. Candelaria M, Cetina L, Pérez-Cárdenas E, de la Cruz-Hernández E, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Chanona J, Arias D and Dueñas-González A: Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynaecol Oncol 3: 386-391, 2010.
47. Carrega P, Pezzino G, Queirolo P, Bonaccorsi I, Falco M, Vita G, Pende D, Misefari A, Moretta A, Mingari MC, Moretta L and Ferlazzo G: Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells. PLoS One 4: E8132, 2009.
48. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Pende D, Biassoni R, Mingari MC and Moretta L: Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 14: 619-648, 1996.
49. Long EO: Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 17: 875-904, 1999.